baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Denali Therapeutics Inc/ US24823R1059 /

10/8/2024 10:00:00 PM	Chg. +0.1300	Volume	Bid10:30:50 PM	Ask10:30:50 PM	High	Low
26.7300USD	+0.49%	557,398 Turnover: 9.81 mill.	26.1100Bid Size: 2,200	32.8200Ask Size: 300	27.4700	26.3000

GlobeNewswire 8/14 Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potent...

GlobeNewswire 8/13 BioHive to launch Returnship Initiative

GlobeNewswire 8/7 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire 8/1 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 6/13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

GlobeNewswire 6/3 Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome T...

GlobeNewswire 5/9 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 5/7 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 5/1 Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343...

GlobeNewswire 4/18 BioHive Announces BioHive Live

GlobeNewswire 4/1 Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Med...

GlobeNewswire 2/27 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...

GlobeNewswire 2/27 Denali Therapeutics Announces $500 million Private Placement Equity Financing

GlobeNewswire 2/7 Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzym...

GlobeNewswire 2/1 Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossin...

GlobeNewswire 1/8 Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its ...

GlobeNewswire 11/27/2023 Meet the Companies Named to Computerworld’s 2024 Best Places to Work in IT List

GlobeNewswire 11/7/2023 Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire 11/7/2023 US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spher...

GlobeNewswire 9/8/2023 Regeneron Announces Updates to Board of Directors

GlobeNewswire 9/7/2023 CENTOGENE Reports First Half 2023 Financial Results

GlobeNewswire 8/30/2023 Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (H...

GlobeNewswire 3/15/2022 Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krog...

GlobeNewswire 3/9/2022 Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Fronto...

GlobeNewswire 2/28/2022 Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlig...

Denali Therapeutics Inc/ US24823R1059 /

If you wish to receive reply to your feedback, please provide your email address.